JP2020517704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517704A5 JP2020517704A5 JP2019558417A JP2019558417A JP2020517704A5 JP 2020517704 A5 JP2020517704 A5 JP 2020517704A5 JP 2019558417 A JP2019558417 A JP 2019558417A JP 2019558417 A JP2019558417 A JP 2019558417A JP 2020517704 A5 JP2020517704 A5 JP 2020517704A5
- Authority
- JP
- Japan
- Prior art keywords
- labeled
- composition
- combination
- cells
- bcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491803P | 2017-04-28 | 2017-04-28 | |
| US62/491,803 | 2017-04-28 | ||
| PCT/US2018/029607 WO2018200841A1 (en) | 2017-04-28 | 2018-04-26 | Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020115411A Division JP2020158544A (ja) | 2017-04-28 | 2020-07-03 | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517704A JP2020517704A (ja) | 2020-06-18 |
| JP2020517704A5 true JP2020517704A5 (enExample) | 2020-08-13 |
| JPWO2018200841A5 JPWO2018200841A5 (enExample) | 2022-06-06 |
Family
ID=63919290
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558417A Withdrawn JP2020517704A (ja) | 2017-04-28 | 2018-04-26 | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
| JP2020115411A Withdrawn JP2020158544A (ja) | 2017-04-28 | 2020-07-03 | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
| JP2023168404A Pending JP2023165952A (ja) | 2017-04-28 | 2023-09-28 | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020115411A Withdrawn JP2020158544A (ja) | 2017-04-28 | 2020-07-03 | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
| JP2023168404A Pending JP2023165952A (ja) | 2017-04-28 | 2023-09-28 | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11364235B2 (enExample) |
| EP (1) | EP3615047A4 (enExample) |
| JP (3) | JP2020517704A (enExample) |
| CN (1) | CN110612109A (enExample) |
| BR (1) | BR112019022308A2 (enExample) |
| CA (1) | CA3059752A1 (enExample) |
| MX (1) | MX2019012660A (enExample) |
| WO (1) | WO2018200841A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019012660A (es) | 2017-04-28 | 2020-07-27 | Actinium Pharmaceuticals Inc | Metodo para tratar cancer empleando un inhibidor de proteina de linfoma de celulas b 2 (bcl-2) en forma conjunta con una radioinmunoterapia con emision de particulas alfa. |
| US20230132400A9 (en) * | 2017-11-10 | 2023-04-27 | Actinium Pharmaceuticals, Inc. | Combination therapy for treatment of a hematological disease |
| JP2022516170A (ja) * | 2019-01-04 | 2022-02-24 | アクティニウム ファーマシューティカルズ インコーポレイテッド | Ｐａｒｐインヒビターおよび抗体放射性物質結合体の組み合わせを使用してがんを処置するための方法 |
| EP4087588A4 (en) * | 2020-01-10 | 2024-10-02 | Fusion Pharmaceuticals Inc. | SUSTAINABLE IMMUNOTHERAPY |
| WO2022055842A1 (en) * | 2020-09-08 | 2022-03-17 | Actinium Pharmaceuticals, Inc. | Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1123202A (en) * | 2000-09-15 | 2002-03-26 | Sloan Kettering Inst Cancer | Targeted alpha particle therapy using actinium-225 conjugates |
| US8487131B2 (en) * | 2009-04-15 | 2013-07-16 | Sanford-Burnham Medical Research Institute | Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2) |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| SG10201913765YA (en) * | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| KR20250067191A (ko) | 2014-09-17 | 2025-05-14 | 노파르티스 아게 | 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화 |
| US20160113925A1 (en) * | 2014-10-22 | 2016-04-28 | Emory University | Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors |
| TW201639573A (zh) * | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| HRP20220893T1 (hr) | 2015-04-08 | 2022-10-14 | Novartis Ag | Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor |
| EP3331546B1 (en) * | 2015-08-03 | 2023-10-04 | Biokine Therapeutics Ltd. | Cxcr4 inhibitor for the treatment of cancer |
| MX2019012660A (es) * | 2017-04-28 | 2020-07-27 | Actinium Pharmaceuticals Inc | Metodo para tratar cancer empleando un inhibidor de proteina de linfoma de celulas b 2 (bcl-2) en forma conjunta con una radioinmunoterapia con emision de particulas alfa. |
-
2018
- 2018-04-26 MX MX2019012660A patent/MX2019012660A/es unknown
- 2018-04-26 CN CN201880027661.XA patent/CN110612109A/zh active Pending
- 2018-04-26 EP EP18792272.9A patent/EP3615047A4/en active Pending
- 2018-04-26 US US16/607,168 patent/US11364235B2/en active Active
- 2018-04-26 WO PCT/US2018/029607 patent/WO2018200841A1/en not_active Ceased
- 2018-04-26 CA CA3059752A patent/CA3059752A1/en active Pending
- 2018-04-26 BR BR112019022308-8A patent/BR112019022308A2/pt unknown
- 2018-04-26 JP JP2019558417A patent/JP2020517704A/ja not_active Withdrawn
-
2020
- 2020-07-03 JP JP2020115411A patent/JP2020158544A/ja not_active Withdrawn
-
2022
- 2022-05-16 US US17/745,045 patent/US11844799B2/en active Active
-
2023
- 2023-09-28 JP JP2023168404A patent/JP2023165952A/ja active Pending
- 2023-11-02 US US18/500,735 patent/US12133849B2/en active Active
-
2024
- 2024-09-30 US US18/901,169 patent/US20250017919A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517704A5 (enExample) | ||
| Eckert et al. | Rationale for combining radiotherapy and immune checkpoint inhibition for patients with hypoxic tumors | |
| Durante et al. | Harnessing radiation to improve immunotherapy: better with particles? | |
| Baas et al. | Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study | |
| Tan et al. | Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial | |
| Khalifa et al. | Radiotherapy in the era of immunotherapy with a focus on non-small-cell lung cancer: time to revisit ancient dogmas? | |
| Stadler et al. | Maintenance therapy in patients with mycosis fungoides or Sézary syndrome: A neglected topic | |
| Hlavata et al. | The abscopal effect in the era of cancer immunotherapy: a spontaneous synergism boosting anti-tumor immunity? | |
| US20220273648A1 (en) | Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic | |
| JP2018520117A5 (enExample) | ||
| Repetto‐Llamazares et al. | Combination of 177Lu‐lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non‐Hodgkin's lymphoma | |
| Dugas‐Breit et al. | New and established treatment options for mycosis fungoides and Sézary syndrome–an update | |
| Braun et al. | Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the F rench‐B elgian‐S wiss APL group | |
| Niibe et al. | High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IIIb adenocarcinoma of the uterine cervix in Japan: a multi-institutional study of Japanese Society of Therapeutic Radiology and Oncology 2006–2007 (study of JASTRO 2006–2007) | |
| Vanneste et al. | An overview of the published and running randomized phase 3 clinical results of radiotherapy in combination with immunotherapy | |
| Gale et al. | Why is there so much therapy-related AML and MDS and so little therapy-related CML? | |
| Revannasiddaiah et al. | Chemically enhanced radiotherapy: visions for the future | |
| Lee et al. | Talazoparib versus chemotherapy in patients with HER2-negative advanced breast cancer and a germline BRCA1/2 mutation enrolled in Asian countries: exploratory subgroup analysis of the phase III EMBRACA trial | |
| Yoshizaki et al. | Progress and controversy for the role of chemotherapy in nasopharyngeal carcinoma | |
| McCluskey et al. | Experimental treatment of neuroblastoma using [131I] meta-iodobenzylguanidine and topotecan in combination | |
| Komatsu et al. | Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with nasopharyngeal carcinoma | |
| Wijnen et al. | Treating CD33-positive de novo acute myeloid leukemia in pediatric patients: focus on the clinical value of gemtuzumab ozogamicin | |
| Weigert et al. | Current management of mantle cell lymphoma | |
| Nagai | Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy | |
| Yang et al. | Duramycin radiosensitization of MCA-RH 7777 hepatoma cells through the elevation of reactive oxygen species |